博大綠澤(01253.HK)組合營建設PPP項目
中國綠地博大綠澤(01253.HK)公布,有關公司為2019年5月6日中標PPP項目一事,私人訂約方(博大綠澤生態、中博建設、上海祝琛、黑龍江華龍及鎮平水利)訂立合營協議,據此,訂約方同意(i)組成合營公司以建設PPP項目;及(ii)規管彼等各自於合營公司的權利及責任。
合營公司之註冊資本將為1.11億元人民幣,鎮平水利、博大綠澤生態、中博建設、上海祝琛及黑龍江華龍將分別按比例出資10%、25%、0.5%、64.4%及0.1%。博大綠澤生態、中博建設及上海祝琛為中國綠地博大綠澤旗下公司;黑龍江華龍及鎮平水利為獨立第三方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.